Tandem Diabetes Care Inc. (TNDM) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, TNDM scores 30 out of 100 and receives a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine (3 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is -2.15%. This is the weakest-contributing area of the framework from a cash-generation standpoint, indicating the business is not currently converting capital into positive free cash flow returns.
• Whale 13F Flow (13 / 20): The rating cites institutional accumulation and options positioning. This is the strongest pillar, though the source does not itemize the underlying 13F holdings (see Analyst View section).
• Insider Conviction (3 / 20): The rating cites SEC Form 4 and Congressional PTR cluster flow. The low score suggests insider and disclosed-trade signals are weak in the framework's view; the underlying trade-level detail is not provided.
• Macro Regime Fit (5 / 20): Per the rating, beta is 1.0 with sector sensitivity noted. Market-level sensitivity is in line with the broad market, but the framework scores macro alignment poorly.
• Forensic Balance Sheet (6 / 20): Per the rating, Altman Z is 0.2, Piotroski F is 4/9, and Debt/Equity is 2. These readings point to elevated financial distress risk under the framework.

For a prospective investor evaluating the stock today, the practical implication is that the score is driven primarily by negative operating economics and balance-sheet forensics rather than by any single weak metric. Upside drivers in this framework would need to come from a reversal in cash generation and balance-sheet strength; the current data shows neither. Valuation tradeoffs cannot be fully assessed because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data, so the stock cannot be benchmarked against earnings-based valuation. The institutional-flow pillar offers the only meaningful positive counterweight, and that is insufficient to offset the weaker pillars. This is an analytical reading of the framework, not personalized financial advice.

Tandem Diabetes Care Inc. (TNDM) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. Per the profile, the company carries a market capitalization of $1.4B. The source data does not detail the company's specific product lines, customer base, or revenue model beyond the sector and industry classification. Reported revenue of $1014.7M for FY 2025 is shown in the SEC financials section, but the underlying revenue composition is not available in source data.

Per the market data, gross margin is 53.8%, operating margin is -18.5%, and net margin is -20.2%. Operating and net income were negative across all three reported periods. Per the Roarable RQD rating, ROIC is -35%, and the forensic balance sheet readings are an Altman Z-Score of 0.2 and a Piotroski F-Score of 4/9, with Debt/Equity of 2. Cash moved from $69.2M in FY 2024 to $90.6M in FY 2025 while debt was broadly flat, with FY 2025 free cash flow negative at $-29.7M.

The news wire contains six items, all related to TNDM. Market-wire items cover general price, options, and institutional positioning coverage from Yahoo! Finance Canada, Yahoo Finance, and Moomoo, with one item noting the stock "may be underpriced given its sales base." A Simply Wall St item is flagged RED under RISK WATCH and is headlined around execution questions and whether the stock is cheap or fairly valued. A Yahoo Finance item notes a possible negative earnings report ahead of the next week's release. A separate Yahoo Finance item covers upcoming conference presentations. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals, so no butterfly-graph catalysts are available.

Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided data. The only sector context available is the Health Care / Medical/Dental Instruments classification. A prospective investor should note that the absence of mapped supply-chain links means this framework cannot identify second-order ripples; any such assessment would require data not in source data.

• What are the P/E, forward P/E, EV/EBITDA, and EPS (TTM) figures, which would allow valuation benchmarking against the RQD rating?
• What are the specific 13F holders, position sizes, and recent changes behind the 13/20 Whale Flow pillar?
• What do the SEC Form 4 and Congressional PTR trades underlying the 3/20 insider score look like in detail?
• What is the FY 2024 and FY 2023 cash and debt position, and what drove FY 2023's negative FCF and missing balance-sheet data?
• What does the Simply Wall St RED risk-watch item identify as the execution concern, and what is the scheduled earnings outcome referenced in the Yahoo Finance negative-earnings item?